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A B S T R A C T
There is a growing recognition that application of mechanistic approaches to understand cross-species shared
molecular targets and pathway conservation in the context of hazard characterization, provide significant op-
portunities in risk assessment (RA) for both human health and environmental safety. Specifically, it has been
recognized that a more comprehensive and reliable understanding of similarities and differences in biological
pathways across a variety of species will better enable cross-species extrapolation of potential adverse tox-
icological effects. Ultimately, this would also advance the generation and use of mechanistic data for both
human health and environmental RA.
A workshop brought together representatives from industry, academia and government to discuss how to
improve the use of existing data, and to generate new NAMs data to derive better mechanistic understanding
between humans and environmentally-relevant species, ultimately resulting in holistic chemical safety decisions.
Thanks to a thorough dialogue among all participants, key challenges, current gaps and research needs were
identified, and potential solutions proposed.
This discussion highlighted the common objective to progress toward more predictive, mechanistically based,
data-driven and animal-free chemical safety assessments. Overall, the participants recognized that there is no
single approach which would provide all the answers for bridging the gap between mechanism-based human
health and environmental RA, but acknowledged we now have the incentive, tools and data availability to
address this concept, maximizing the potential for improvements in both human health and environmental RA.
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1. Introduction
It is recognized that new scientific improvements and their in-
tegration in risk assessment have the potential to improve human
health risk assessments by enabling a mechanistic understanding of
adverse effects and more accurate predictions of biological responses
(Bennekou 2019). Current regulatory-accepted approaches to assess
chemical safety are often based on a battery of in vivo methods and a
limited number of accepted in silico or in vitro approaches. However,
performing toxicity studies for all existing chemical substances using in
vivo methods is not physically, ethically, or financially possible. Che-
mical or biological read-across approaches are being considered by
industry and chemical management agencies as an alternative to reduce
the reliance on these highly resource-intensive in vivo tests. There is an
urgent need to improve current capabilities to perform chemical read-
across and cross-species extrapolation (biological read-across) through
an improved mechanistic understanding of the basic biology underlying
toxicity and the chemistry-biology interactions involved. Development
of descriptors and alerts that facilitate chemical grouping and a better
understanding of the species hazard space (i.e. species that are sensitive
to certain chemical classes) would also be highly beneficial. In this
respect, there have been many efforts focused on the challenges in-
volved in the development of chemical read across, improving its sci-
entific justification and supporting documentation for use in both
chemical hazard and RA. Chemical read-across and grouping ap-
proaches have become some of the most commonly used alternative
approaches for data gap filling within analogue and category ap-
proaches (Patlewicz et al. 2013). These efforts have led to a wide re-
cognition of the scientific validity of these and its regulatory acceptance
and recently, ECHA has published a guidance document on how to
perform and document chemical read-across under REACH (Read-
Across Assessment Framework (RAAF)) (ECHA 2017).
Over the last two decades, there has been a scientific and regulatory
push toward the development of novel non-animal approaches for
safety assessment (Krewski et al. 2010). There is a growing desire
within the scientific community to achieve simpler, broader, faster and
importantly, more predictive risk assessment (RA). To achieve the de-
sired improvements in chemical RA, the current limitations concerning
the generation, integration and interpretation of newer types of data
proposed for use in RA need to be overcome. Recent developments in
biotechnology and molecular biology have given rise to New Approach
Methodologies (NAMs) (Kavlock et al. 2018) that are greatly enhancing
our ability to address some of the data gaps faced in both human and
environmental toxicology. NAMs are a recently adopted concept to
broadly refer to any non-animal approach, methodology and/or tech-
nology, aimed at providing information on chemical hazard and RA,
including integrated approaches to testing and assessment, data inter-
pretation, and performance-based evaluation of test methods (ICCVAM
2018). NAMs open new opportunities to ensure RA is grounded in
human biology rather than replicating the results of a prescriptive list of
animal tests. This is especially important for mechanism-of-action-
based RA. For instance, effect concentrations based on perturbations in
signalling pathways in human cells will likely be different from those
causing apical effects during rodent studies. The difference in species
and level of biological organization considered in the example suggest
that results of such tests cannot (and should not) be ‘validated’ against
each other and should be compared with caution (Dent et al. 2018). In
this respect, the use of molecular-based, high content data has the in-
nate potential to complement traditional human and environmental
toxicology approaches (Aguilera et al. 2018; Brockmeier et al. 2017;
Campos et al. 2018; Van Aggelen et al. 2009). Indeed, their use could
catalyse a paradigm shift to more proactive pathway-based approaches,
ultimately facilitating the development of in silico-based predictive
toxicology (Buesen et al. 2017; Sauer et al. 2015). Available data on
endpoints supporting traditional approaches to assess environmental
and human safety, coupled with a growing weight of in silico/in vitro
biological pathways-based data raise the question: are we already at a
point where we can consider new types of data and incorporate them in
a new or augmented approach to RA?
For this to happen, frameworks such as the Adverse Outcome
Pathway (AOP) concept, which links the description of biological cas-
cade from the insult at the molecular initiating event (MIE) to the ad-
verse outcome (i.e. AO - the apical toxicological endpoint of concern),
can be utilised (Ankley et al. 2010; Villeneuve et al. 2014; Vinken
2013). In addition to the mapping of data, the AOP concept also allows
for qualitative evaluation of a pathway and its overall reliability
through a weight-of-evidence approach (OECD, 2017). In some cases,
for example in the regulatory assessment of endocrine disruption ha-
zard, a weight-of-evidence-based approach has been advocated
(Andersson et al. 2018). However, the next and ultimate step required
for this approach to be fully implemented in RA is the development of
its quantitative aspect (Perkins et al. 2019; Margiotta-Casaluci et al.
2016).
Use of cross-species extrapolation is a well-established concept for
RA for environmental safety (e.g. using toxicity data from a reduced
number of model species to represent the entire ecosystem biodi-
versity), but also for human health (e.g. using laboratory studies from
rodents to infer effects on humans). However, an improved, more
comprehensive and reliable extrapolation of biological pathways across
species would facilitate the use of already available toxicity data across
human health and environmental RA and allow for a more coherent and
efficient characterization of overall hazard (Péry et al. 2013). Whilst the
potential of molecular-based, high-content data and mechanistic ap-
proaches has been recognized(Kavlock et al. 2018; Celander et al.
2011), there are limited examples where molecular level data have
been extrapolated across species, including human, to inform cross-
species mechanistic understanding as part of the next-generation RA of
chemicals(Kavlock et al. 2018; Forbes and Galic 2016; Sauer et al.
2017). There is an urgent need for new approaches to classify and
(ideally) quantify inter-species similarities/differences based on me-
chanisms of action. However, there are some pragmatic first steps that
can be taken using emerging and developing technologies (including
OMICS) (Altschul et al. 1990; McRobb et al. 2014; Walker and
McEldowney 2013).
Motivated by these questions (Fig. 1), a workshop was organized,
entitled “Vision of a near future: bridging the Human Health - en-
vironment divide. Roles of molecular and data-rich approaches as part
of an integrated strategy to understand mechanisms across species for
chemical safety assessment”, held at Colworth Science Park (Sharn-
brook, UK) on April 18th–19th, 2018. Representing academia, industry
and government, thirty experts were brought together from diverse
fields, including human and environmental toxicology and regulatory
safety science, to foster this dialogue. The overall purpose was to dis-
cuss how existing data can be better exploited and how new data can be
generated to improve mechanistic understanding across humans and
environmentally relevant species to better inform chemical safety de-
cisions.
2. Workshop outline
Participants were selected based on their domain of expertise as
well as their affiliation, to ensure a broad coverage both in sense of
background and areas of interest as action domain. Stakeholders from
universities (U. Cambridge, U, California Berkeley, U. Birmingham, U.
Liverpool, U. Exeter, U. Amsterdam, Brunel U.), private sector i.e. in-
dustries (Unilever, Astra Zeneca), and governmental/regulatory bodies
(USEPA, EC-JRC and NC3Rs) were invited to discuss current problems
and needs concerning biological read-across and its implementation in
current practices of RA. New strategies and solutions were also pro-
posed.
In preparation for the workshop, delegates were asked to reflect and
share their opinion on two key questions prior to the event:
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(1) what are the main drivers to develop cross-species understanding of
mechanisms of action in the context of RA?
(2) what approaches/techniques do we foresee as better suited to
provide scientific evidence and increase confidence in cross-species
extrapolation and what are the main limitations?
All feedback received was analysed and provided the basis for a
focussed discussion in breakout groups. Based on their expertise and
opinions shared prior to the workshop, delegates were divided into
three work groups, each addressing a different level of biological or-
ganization: (WG1) target-level, (WG2) pathway-level and (WG3) phy-
siological-level, including exposure. Each group was asked to discuss
the current science and knowledge available and the scientific research
needed to achieve full potential as outlined in Table 1, focusing on the
main challenges, benefits and hurdles.
3. Breakout discussion group summaries
3.1. Work group 1: “The challenge: improve our knowledge of MIE across
species”
Key shortcomings regarding the use of MIEs (the initial chemi-
cal–biological interaction that starts the AOP (Allen et al. 2016)) to
identify and understand common pathway signal transduction for cross-
species extrapolation were considered by WG1. When considering a MIE
for RA across human health and the environment, it is important first to
recognize that there are different aims and diverging protection goals. In
fact, for humans the protection goal is optimally set at the individual
level, aiming at protecting each individual against harm; for the en-
vironment, this is more often established at the population or ecosystem
level (Hommen et al. 2010). Similarly, there may be varying layers of
complexity to consider, for example general narcosis vs. specific Mode of
Action (MoA), or a MIE with multiple interactions (e.g. skin sensitizers)
vs. a MIE that leads to one specific adverse event (e.g. estrogenic receptor
agonist). Challenges also differ substantially depending on the goal for
extrapolation between datasets/species, i.e. to assess for a similar MoA/
AOP (or toxicity pathway) across species or to extrapolate effect levels
across species. If the aim is to assess for similar MoA/AOP across species
(but not effect levels), current state of the art ortholog predictions (e.g.
OrthoDB (Kriventseva et al. 2007) or EggNOG (Jensen et al. 2007)) can
provide a good starting point, provided the mechanism of toxicity is
specific and the MIE limited to one (few) specific protein targets. How-
ever, there are many uncertainties associated with ortholog predictions.
For example, uncertainty increases with evolutionary distance between
species as well as for some types of protein families such as CYP450 or G-
proteins (Katritch et al. 2012). In the pharmaceutical field this has been
Fig. 1. Holistic schematic of how to perform chemical risk assessment using mechanistic knowledge improving the cross-talk between human health and en-
vironmental safety.
Table 1
List of the challenges considered by each of the three working groups.
Challenge 1 Improve basic knowledge of Molecular Initiating Events (MIE) across species
● Improve knowledge of target homologue/orthologue characterization through evolutionary (and functional) conservation
● Develop an understanding of the chemistry of MIEs with a cross species perspective
Challenge 2 Develop basic knowledge of pathway conservation across species
● Increase scientific knowledge for pathways-based comparison to support extrapolation from a higher-tier perspective
● Develop species-specific pathway-to-phenotype association analysis in a chronic exposure scenario
Challenge 3 Refine understanding of biological processes impacting internal exposure
● Understand species-specific physiological processes (ADME) to predict chemical effective doses at the target site in different species
● Develop and refine PBK models for key species and link them to understand where there are common and species-specific processes
This report describes the proceedings of the workshop and presents the highlights of the discussion. All opinions were treated equally and were consensually
accepted by all participants.
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addressed by using a majority vote across three prediction platforms in a
web-based application that looks for protein target conservation between
human and a range of sequenced phyla (www.ecodrug.org) (Verbruggen
et al. 2017). Furthermore to this, another tool facilitates summary,
comparison and access to various sources of ortholog predictions and
provides a comparison of 17 different tools and algorithms to increase
the confidence in the orthologue prediction (http://www.flyrnai.org/
diopt) (Hu et al. 2011)
To understand how a MIE could be used to inform RA and enable
cross-species extrapolation, the extent of functional conservation of
downstream effects across species also needs to be resolved. This could
be achieved by deploying new functional in vitro assays, although this
is expected to be time and resource intensive. However, some com-
pounds will interact with multiple targets, and may lead to different
downstream events. This highlights the importance of understanding
the response of biological systems from a network perspective
(Margiotta-Casaluci et al. 2016; Knapen et al. 2018). Moreover, since
chemical-target(s) interaction networks are often driven by internal
exposure dynamics, it is also essential to enhance the understanding of
adsorption, distribution, metabolism and excretion (ADME) processes,
especially in lower species, where current knowledge is limited. This
will allow enhanced consideration of chemical-target interaction net-
works that may occur following diverse exposure scenarios, thus sim-
plifying and boosting the cross-species extrapolation process.
Furthermore, it was agreed that the pathway leading to the AO itself
needs to be fully understood to prioritize testing needs. Understanding
how gene/proteins relate to downstream functions through evolu-
tionary relationships between protein families and super-families may
also be informative and more meaningful than a one-to-one compar-
ison. Therefore, it is important to understand the available data in-
cluding substrate specificity and related potencies to discern how the
level of gene/protein similarity influences the target affinity and the
impact on potency.
While doing so, it is important to keep in mind the whole decision-
making process, to better and more efficiently define what is the
minimum but necessary information required to enable decision-
making for RA purposes and thus reduce overall uncertainty. Pertinent
to this, it will also be paramount to consider the different needs of
different stakeholders (e.g. regulators vs. industry).
The need for a deeper understanding of the difference between re-
ceptor-mediated and more general stress responses was also discussed.
Potential solutions included the idea of developing directed functional
bioassays, as well as building a library of target-knockout systems en-
compassing several species. To ensure meaningful results and application,
any of these approaches would need to make use of a broad selection of
chemicals, representing a variety of chemical classes and MoAs/AOPs, as
well as to cover different suitable exposure durations and time points
(including life stages), ensuring coverage of potential sources of varia-
bility. Ultimately, these approaches would generate a repository which
could then be interrogated for hazard characterization every time a new
substance comes in for hazard evaluation. There are already ongoing ef-
forts pointing to this same direction, including the Library of Integrated
Network-Based Cellular Signatures (LINCS) Program (http://www.
lincsproject.org/) (Duan et al. 2014), providing a first attempt to create
a network-based library of biological signatures by cataloguing changes in
gene expression and other cellular processes occurring when cells are
exposed to a variety of perturbing agents. While this represents a pow-
erful source of information, it is currently limited to human and more of
these kinds of approaches are needed to support the evidence across
species. Nevertheless, it is recognized that chemical exposure levels in the
environment are often very low at a cellular level and producing assays
with environmentally relevant cellular exposure becomes difficult (re-
iterating the need for cell level exposure considerations). Another dis-
cussed alternative, and potentially more efficient, way to test this concept
would be to start using available data, comparing current existing human
toxicity signatures (for instance, from the LINCS database, among others)
to available historical toxicity records in the ecotoxicology literature. The
proposed database would be used as a surrogate to define the biological
target space and could be interrogated to identify potential consensus
hazard signatures, based on effect conservation. However, this approach
would also pose several other practical questions: what data types would
that database include, such as life-history, transcriptomics, metabolomics,
etc.? On which species and chemicals? How would it be prioritized? All of
these questions highlighted the recurrent need to increase the ecological
realism by considering a larger number of species and thus, related de-
livered ecosystem functions. This also implies that thorough predictions of
pathway-based signatures are urgently needed to better estimate risk,
especially when trying to define the most relevant/appropriate species
under each scenario. Increasing the two-way data flow (human health to
ecotoxicology and vice-versa) would undoubtedly improve the under-
standing in this field.
The final note from the Work group 1 discussion was the recognition
that environmental RA information is not currently being fully
exploited within the human health arena (and vice-versa). In fact, there
is still a great potential for developing additional biological read-across
and extrapolation processes from human health to environmental safety
science (and vice-versa), but their different needs and priorities need to
be acknowledged. In this sense, generation of new data may not be a
priority need, but rather the development of new/improved data
mining tools to interrogate the wealth of data that is already available.
3.2. Work group 2: “The challenge: develop our basic knowledge of pathway
conservation cross-species”
This group addressed how to tackle cross-species extrapolation at a
pathway-level and discussed several key issues that need to be resolved
to increase confidence before application. It was identified that gene
function is the crucial aspect in this respect and the concept of “func-
tional orthology” (Gabaldón and Koonin 2013) was considered a ben-
eficial approach to predict the conservation of the (adverse) outcome
across species. To address and expand this concept, investigations on
different levels are needed. (Re)defining and cataloguing the orthologs
by function would help sorting and functionally annotating them into
the relevant pathways. There is high probability that a number of genes
and gene subfamilies are divergent across species, and additionally,
multi-purpose enzymes found in lower species may replace their role
and thus belong to multiple pathways. A first attempt in this same di-
rection is provided by the new available software Gene2Function
(http://www.gene2function.org/) (Hu et al. 2017) whose primary goal
is to facilitate the development of new hypotheses regarding the func-
tion of a given gene based on what is known about the function of
orthologs of that gene in other species.
Going beyond a better functional annotation, before stepping-up to a
purely pathway-level analysis, the need for a more human and environ-
mental toxicology-relevant gene annotation was also acknowledged. In
fact, essential genes/gene families involved in human health (inferred by
the many medical/pharmacological studies available) may not always be
the same as those that are of ecotoxicological concern. Therefore, as a
possible solution, it was suggested to map the human genome against
existing ecotoxicology literature in a newly designed, fit-for-purpose da-
tabase, thus re-annotating genes based on ecotoxicological needs.
The participants acknowledged attempts to define all known AOPs
in human and environmental toxicology, however the data are cur-
rently far from complete and little is known about cross-species eva-
luation. The need to define a priority list of the most relevant pathways
was discussed and agreed it would provide a good starting point for
deeper exploration. One proposed hypothesis was that the “key” path-
ways that are essential for life are likely to be the more evolutionarily
conserved. These could include pathways such as oxidative stress, Nrf2,
the p53 DNA damage response, the unfolded protein response (UPR)
and mitochondrial injury, among others (Jennings et al. 2013). Ex-
ploration here should be focused both on improving understanding on
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both an evolutionary scale and on an experimental level. For example,
it was suggested the creation of a priority pathways screening panel
across relevant species, including new in vitro assays for toxicity and
stress responses coupled with Physiologically based Kinetic (PBK)
models. However, improved insights on the level of pathway con-
servation is required to be able to interrogate their (potential) de-reg-
ulation to the initiation of apical effects (or the lack thereof). This
would also serve to improve the functional annotation of the pathways
themselves, as mentioned above, thus developing a new “apical func-
tional ontology”. Though, even if some of the pathways are conserved
between species, the apical endpoint might not be present, could be
organ-specific or could manifest itself in a different (not directly iden-
tifiable) way. AOP-Wiki (https://aopwiki.org), the central repository
for all AOPs developed so far, represents a good source of information
to identify the known links between MIEs, and the cascade of key events
(KE) leading to the apical endpoints/AO (Villeneuve et al. 2014). A
good example of the former is AOP 150 “Aryl hydrocarbon receptor
activation leading to early life stage mortality, via reduced VEGF”
where the developing embryos of birds and fishes are most sensitive to
the stressors activating this AOP, ultimately leading to embryo death
and population trajectory decline; mammals appear to be less sensitive,
leaning toward cardiotoxicity that persists into adulthood, and in-
creasing susceptibility to heart disease rather than embryo-lethality. It
was also discussed that sub-pathway modules/key events might be
more conserved, thus easier to track, and might give more information
between different species than investigating the whole pathway. While
it is appreciated that we cannot expect to unravel all AOs for all toxicity
pathways of concern in all species, moving toward these kinds of ap-
proaches would help to increase confidence in toxicity predictions.
Also, it would be a significant advancement to know when a pathway is
conserved and disrupted across which species, thus defining with more
confidence the space for environmental risk.
In this respect, it was acknowledged that the aim of research is al-
ways to advance science to serve society with the maximum knowledge
possible. As scientists, it is appreciated that curiosity drives the un-
derstanding of every mechanism and interaction between a chemical
and an organism. Regulatory pressures require data underpinning
human health or ecological assessment to be consistent and robust, with
the goal of ensuring safety to humans and the environment. This raises
the challenge: when do we have enough data for RA? An admittedly
complex question to which there is no easy answer. The ultimate goal is
to achieve enough confidence to enable decision-making without end-
less laboratory testing and years of research. Starting from the point
that it is not realistic to cover all aspects for assessment contexts, it was
suggested that it may be easier to know when the data is not enough. It
is a matter of increasing confidence and reducing uncertainty: for in-
stance, one could hypothesize that enough data might mean having
several pathways annotated to allow satisfactory toxicity predictions,
although we don't know all of them. Thus, to answer the question on
how much investment is acceptable to reduce the uncertainty of risk,
we first need to think of how current uncertainties are preventing de-
cisions to be made and how much we are willing to invest (in time,
money and effort) to improve this certainty. The current revolution in
digital technology and machine learning approaches may well help to
address both the question of how much data is required, and what in-
formation is retrievable from existing data (Miller et al. 2018).
From an environmental RA standpoint, it will never be possible to
consider all environmental species and all possible exposure scenarios
(time, doses, frequency and ecological circumstances). As such, there is a
need to derive sufficient evidence allowing to build models and provide
enough scientific basis to support reasonable predictions based on rela-
tively small datasets. There is not one unique environmental relevant
species that is better, more representative or more appropriate than
others. A concept currently being explored by evolutionary biologists
considers several species (5–8 species) covering the phylogenetic tree in
its main branches. This could be considered the minimum number of
species needed to reflect the main distinctiveness of evolution. In any
case, it continues to be very challenging to include species-specific
physiology into the equation as well as the ecological traits that are
unique to each (sub-)species. Similarly, it is important to understand how
to consider and account for genes that may exert different roles si-
multaneously, or different functions throughout the lifetime of the or-
ganism; how to deal with epigenomics and the knowledge that genomes
are adaptive to environmental conditions and/or external stimuli; how to
overcome the potential problem that genes may behave differently when
tested in controlled lab conditions as compared to their native state. All
of these remain open questions: although much work has been done to
try to answer these questions, comprehensively addressing these and
other concerns on a case-by-case basis are still far from application and
beyond the current requirements for RA.
3.3. Work group 3: “The challenge: refine our understanding of biological
processes impacting internal exposure”
Consideration of the main biological processes impacting internal
exposure, and particularly, how species-specific ADME processes influ-
ence chemical concentrations at target sites, is critical to the application
of mechanistically-based species extrapolation. The concept of “exposure”
cannot usefully be discussed in isolation, but rather as an integrated part
of the RA question. Without inclusion of exposure, any discussions on
chemical-target interactions and species extrapolation of the responses
remain theoretical, limited purely to the identification of similar hazards.
In order to translate an identified hazard into a risk, considering and
understanding exposure is essential. Being RA is driven by exposure, it is
not relevant that the molecular target triggered by a given compound is
conserved across species, if the exposure level is below the activation
threshold of the MIE. Thus, it becomes essential to understand the RA
question, and link to the specific exposure scenario, and the required level
of confidence needed to make an early decision on risk. At sufficiently
high chemical exposure doses, organisms and cells often exhibit acute
effects related to general membrane perturbation, e.g. narcosis, whereas
at continuous but lower doses, different pathways may trigger measurable
effects at various thresholds. In addition, complexity is also added by
differences in sensitivity between different cell types as well as different
rates of metabolism across tissues and organisms. Indeed, when extra-
polating from in vitro to in vivo, or from species to other species, dif-
ferences in both biokinetic and biodynamic properties are of central im-
portance and neither can answer the question of risk independently.
Lessons can be learned from human health where for decades an-
imal effect data have been utilised to extrapolate to potential human
effects. More recently, research has been focused on extrapolating from
in vitro to in vivo effects to eliminate and overcome the need for animal
testing. The magnitude of the challenge of applying the same strategies
to environmental RA is apparent: rather than dealing with one very well
characterised organism, thousands of diverse, highly variable and
poorly characterised organisms need to be considered. Given this
complexity, the workgroup focussed discussion mostly around fish,
where extrapolation approaches from existing data is key, given the
desire to eliminate animal (i.e. vertebrate) testing.
In order to meet these needs, the MERLIN-Expo software (https://
merlin-expo.eu/) was developed, which contains a library of models for
exposure assessment coupling environmental multimedia and pharma-
cokinetic models, and aims to link environmental fate of chemicals and
internal concentrations in humans, thus integrating environmental ex-
posure assessment and human exposure assessment. Although it re-
presents a very significant step in this space, it is centred over human
health RA and does not cover the heterogenicity found in the en-
vironment in terms of species and ecosystems, that still need to be
addressed further for its implementation in ERA.
Across the pharmaceutical industry as well as pesticides and bio-
cides, chemicals of interest are designed for high levels of specificity
and potency, and effective absorption. This combination of chemical
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attributes can often lead to measurable effects at realistic exposure
scenarios for aquatic species despite being designed for low bioaccu-
mulation potential (Miller et al. 2019). As such, there has been a
pressing need for a common strategy for environmental RA for these
industries. In contrast, ingredients used in Home and Personal Care
(HPC) products are designed to be of low bioactivity as possible. As
such, toxicological concern associated with these types of chemicals is
reduced, though the volumes used are greater compared to pharma-
ceuticals, for example.
It is therefore understandable that the greatest examples forward in
terms of MIE identification and species extrapolation come from the
pharmaceutical sector. One of the most prominent strategies for en-
vironmental RA coming from this sector is the Hugget approach (Fig. 2)
(Fitzsimmons et al. 2001; Tanoue et al. 2017; Valenti Jr et al. 2012;
Huggett et al. 2003). This method presents an approach for biological
read-across from human therapeutic doses to environmental species
(e.g., fish). It rather simplistically compares internal concentrations in
fish and human based on toxico-kinetic modelling and environmental
fate calculations.
However, the application of this approach in other sectors is more
challenging because, for instance, HPC ingredients rarely have a full
package of ADME data associated with them, predominantly because they
were not designed for biological interaction in the same way that phar-
maceuticals are. This could suggest that for many chemicals the Hugget
approach may be excessive due to its extensive data requirements.
However, the exploitation of existing data from other compounds or from
other species may obviate the need for extensive testing if the uncertainties
surrounding these data can be addressed. These uncertainties result from
1) whether we can assume metabolic machinery is significantly similar
across species to predict metabolism in relevant species and 2) whether the
potency of target effects is the same in different species.
Given the relative abundance of data generated regarding human
metabolism, a consideration to be made regards how acceptable it is to
read across from data generated to satisfy human safety needs (using in
vitro assays) to fish and other species. This raises a number of research
questions: a) Can we cover all the biological space for fish using existing
human cell lines? b) Can we use existing cell line data sources (e.g.
American Tissue Cell Collection or Cellosaurs) to define suitable cell
lines to cover that biological space? c) have we performed extensive
comparisons between these human-fish cell lines and if required can we
establish new lines to fill the gaps? d) Can we use existing untargeted
chemistry data e.g. a metabolomics study, to see and/or model meta-
bolism patterns for selected chemical classes across human and model
species? Can we take broader approaches for understanding
metabolism in environmental species? For example, can we classify
clearance in fish as high-medium-low and can we establish uptake rates
for chemical classes? In this regard, the workgroup also discussed the
possibility to perform computational simulations to address the un-
certainty across a range of species and use randomness to generate
draws from a probability distribution. Main strength of this approach is
the possibility of considering any potential outcome of a process and
thus, assessing the whole impact of risk and allowing for better decision
making under uncertainty and deficiency of data.
When looking into the application of these approaches for RA, it was
acknowledged that additional careful consideration is needed in de-
signing a new exposure-driven environmental RA strategy. The con-
ventional Predicted Environmental Concentration/Predicted No Effect
Concentration (PEC/PNEC) strategy for assessing environmental risks is
often criticised for its lack of environmental realism and its con-
servative nature. The strategies adopted by the pharmaceutical sector
require extensive data generation that may not always be feasible for
other products or ingredients. However, a strategy based on max-
imizing read-across data from other species principally focussing on
understanding and characterising metabolism may negate the need for
large-scale metabolism data generation. Additionally, this should en-
ableto maximize the value of existing PBK approaches to establish in-
ternal exposure concentrations as part of a broad modelling approach
for environmental RA. Gaps in knowledge still exist in order to de-
termine which approach is most appropriate and more species-specific
PBK models and metabolism data is required to be generated to support.
Overall, the group concluded that there is a need to develop further
approaches to capitalize on the advances made in molecular target
discovery and being able to determine internal exposure to a sufficient
level of accuracy, whilst still maintaining a pragmatic approach.
4. Discussion and future outcomes
Over the last decade, there has been advancement in the way that
chemical RA is performed and there has been an accelerating global
shift toward animal-free methods. The International Cooperation on
Cosmetics Regulation (ICCR) recently defined Application of ‘Next
Generation RA’, as an exposure-led, hypothesis-driven RA approach
that integrates in silico, in chemico and in vitro approaches, and pro-
vides an example of how this framework is becoming more embedded
(Dent et al. 2018). Nevertheless, current environmental RA standard
regulation guidelines still rely on extrapolating largely in vivo data
from a limited number of model species to a multitude of species of
environmental concern using safety factors to account for uncertainties.
Fig. 2. Hugget approach scheme. Acronyms PoD: Point of Departure, PBTK: Physiologically-based ToxicoKinetics.
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This protective rather than predictive (or realistic) approach to biolo-
gical read-across presents significant barriers to the broader use of the
increasing wealth of NAMs-derived data for inferring impacts across
organisms within a Next Generation RA framework. At present, biolo-
gical read-across tends to be constrained by its large degree of un-
certainty due to inherent physiological diversity (obvious at the organ
to species-level, but less obvious at the sub-cellular MIE-level), the wide
range of sensitivities to chemicals and the limited mechanistic under-
standing of toxicity in non-target species. In fact, the general lack of
comparative cross-species sensitivity data (including human) limits the
ability to make robust taxonomic extrapolations in support of RA.
Overall, it is essential to increase trust in these methods, by building
confidence among regulators and the broader scientific community that
the necessary biology is comprehensively and adequately incorporated
into the proposed animal-free strategies, so that they can be applied and
used for both human health and environmental RA. To encourage this
process and to reduce the associated uncertainty, it is imperative to
identify and explain the relevant inter-species similarities/differences,
to allow more evidence-based extrapolations and an improved assess-
ment of uncertainty.
There are several ways to achieve this. A common concept is based
on pure orthology, which relies heavily on sequence similarity and
phylogenetic events, and is illustrated by SeqAPASS (Sequence
Alignment to Predict Across Species Susceptibility, https://seqapass.
epa.gov/) (LaLone et al. 2016). This tool attempts to answer the
question whether or not a known protein target is present in another
species for a chemical to act upon. Information from SeqAPASS, in
concert with AOP descriptions can begin to inform the potential for
cross-species effects propagating from a MIE to an AO. Another ap-
proach “Interspecies Correlation Estimates” (https://www3.epa.gov/
webice/) (Raimondo et al. 2007), was developed by the USEPA with
two aims: the estimation of acute toxicity from a surrogate species, and
a species sensitivity distribution model which generates a prescribed
hazard level. The main disadvantage of this approach is that it is based
on statistical inference and modelling and is not inclusive of any bio-
logical or mechanistic information. While acknowledging the added
value of these approaches in providing additional lines of evidence
applicable to a WOE evaluation in a decision-making context, they
presently still lack the underlying mechanistic understanding needed to
improve safety decisions. Yet, the tools are not static and continue to
evolve as the science advances in this area of bioinformatics.
The workshop discussed the opportunity for application and the
limitations of the current approaches, along with proposing NAMs that
could improve biological read- across while reducing the inherent un-
certainty embedded in the process. At the same time, it would allow
greater re-use of existing data sources. In this regard the main outcomes
of the workshop can be distilled into an augmented concept of “functional
orthology”, in which the common orthology concept should be merged
with functional and mechanistic information, namely the information
being generated by ToxCast, SEURAT-1, EU-ToxRisk projects among
others (Daneshian et al. 2016; Gocht et al. 2015; Kleinstreuer et al. 2014;
Berggren et al. 2017), thus expanding the understanding of the under-
lying processes leading to toxicity. Although this is not a completely new
concept, it is only now that the latest advances in technology and
knowledge will allow “functional ontology” to be fully achieved. In this
perspective, the most effective and unbiased way to determine gene
function is through functional genomic studies, which usually involves
(systematic) knockout of genes, followed by assessment of phenotypes
such as lethality/viability, growth, development, etc. These “genotype-to-
phenotype” approaches can also provide insight into chemical mechan-
isms of action, helping to define more specific toxicological endpoints and
informing the development of novel mechanistic-based toxicity bioassays.
New powerful molecular techniques are now available to obtain targeted
knockouts, such as homologous recombination, RNA interference (in-
cluding siRNA and shRNA), engineered site-specific nucleases (i.e. zinc-
fingers, TALEN, CRISPR). However, using only sequence homology (and/
or orthology) as a basis for extrapolation may be somewhat limited (as
discussed previously) and not a guarantee of the conservation of function.
Thus, managing to overcome this assumption by considering the func-
tional level would lower the ambiguity and reduce overall uncertainty.
The translation of these new understanding into novel pathway maps
could be used to better define the species-impact space for well-defined
toxicity pathways. This is not a trivial task; though, if collective and co-
ordinated efforts are brought forward, ensuring gaps are addressed a by
all the relevant stakeholders and new knowledge is then translated into
regulatory changes, the benefits for both human health and environ-
mental RA are expected to be highly significant.
Since most of the currently generated NAMs data are designed to
inform human health assessment, ecotoxicology has much to gain from
an increased knowledge of pathway homology. There is high potential
to benefit from a comprehensive and well understood mechanistic-
based predictive science, addressing the long-standing issue of chronic
(i.e. long term) sub-lethal exposure. Nevertheless, there are also po-
tential advantages for human health RA, such as the concept of new
PBK and dynamic models developed for chosen invertebrate species
that may be the missing piece of the puzzle and provide the evidence of
whole-organism function. This will offer human health researchers a
new multi-dimension, fully functional biological model, helping better
inform the processes involved in toxicity and/or disease. Human health
researchers have recently developed several approaches to overcome
the shortcomings of single cell line testing (e.g. lack of biological re-
levance, impaired metabolism) by using multicell plates, organotypic
3D models, among others. Although a big step forward and more re-
levant in vivo conditions, these approaches may not yet be sufficiently
representative of the dynamics of a whole organism. In this sense, the
development of a deeper biological/physiological knowledge of in-
vertebrate species and how they deal with stress, can have a large im-
pact. Existing vertebrate-based PBK models can already provide valu-
able information on internal concentrations (particularly in fish) to
support RA decisions, although broader applicability of such models
may be obtained through closer investigation of data read-across po-
tential for some input values and the associated uncertainties.For in-
stance, until recently, when considering the traditional protection goal
of environmental RA as the population level, decision-making, has
largely been based on the test chemical concentration able to disrupt
apical processes, (i.e. development, growth, reproduction, and survival)
in environmental species, which may ultimately alter population dy-
namics. In this regard, the issue of estrogenic chemicals in the aquatic
environment provides an interesting example of the practical sig-
nificance of this aspect. The intersex condition (i.e. presence of eggs in
the testis) observed in male fish in the rivers of many western countries
is probably one of the most dramatic phenotypic effects observed in
freshwater wildlife associated with chemical contamination (Jobling
et al. 1998; Sumpter and Johnson 2008). The discovery of intersex in
wild fish, in the 1990s, triggered an entirely new stream of research,
endocrine disruption in the aquatic environment. The evidence pro-
duced by this large volume of research led, in 2015, to the inclusion of
17-Alpha-ethinylestradiol (EE2), 17-Beta-estradiol (E2), and estrone
(E1) in the surface water Watch List under the Water Framework Di-
rective. However, concurrently, a large study carried out in the UK
demonstrated that populations of cyprinid fish are self-sustaining de-
spite widespread feminization of males (Hamilton et al. 2014), raising a
new challenge for the interpretation of the relevance of testicular in-
tersex for decision-making in environmental RA. This suggests that
more efforts should also be dedicated to the evaluation of whether
implementation of the latest mechanism-based predictive toxicology
approaches would bring significant benefits compared to the traditional
approach. Regardless the aim of the RA, predicting adverse phenotypes
triggered by exposure to chemicals remains an essential aim of modern
toxicology. This challenge is particularly pressing if we consider that
millions of animals would be required to test the potential toxicity of
the thousands of chemicals currently in commerce. The application of
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the AOP concept to frame existing toxicological knowledge from a
mechanistic perspective has been proven to provide a good platform to
bridge the gap between human and environmental RA (Margiotta-
Casaluci et al. 2016), and to support the regulatory acceptance of me-
chanistic considerations in an environmental RA context.
5. Conclusion and recommendations
Overall, the workshop highlighted a clear and common motivation
to progress toward the application of mechanistic-based animal-free
chemical safety assessment methods. However, there is no single fit-for-
all approach and it is clear that seldom will be possible to directly re-
place animal testing with NAMs, but rather coordinated efforts aimed at
an integrative implementation of new approaches are required. As a
first step, it was urged further exploitation and integration of the wealth
of already available information. Better employment of existing data
and tools may drive toward an improved cross-species extrapolation
and lead to reduced reliance on animal data. This is particularly true for
environmental toxicology where similar tests are traditionally required
in multiple species to meet global regulatory requirements, but also
useful to bridge the existing knowledge gap between human and en-
vironmental toxicology. Moreover, further targeted development of
NAMs and generation of ad-hoc data would greatly increase confidence
and scientific evidence for extrapolating MIEs, KEs, or entire pathways
(e.g. MoAs/AOPs) between human and environmental relevant species,
thus consolidating the shift to a more mechanistic-based predictive RA
and support the use of a broader landscape of data across both human
health and environmental RA fields.
The identified and prioritized research needs and key re-
commendations from the workshop cover both current technical chal-
lenges (i.e. required research & capability-build) and decision-making
challenges (i.e. development & evaluation for RA), as follows:
● Research needs:
o To setup collaborations between relevant stakeholders (academia,
industry, regulators, NGOs) to define endpoints or AOs of concern
across human models and environmental species, leading to
prioritized testing needs.
o Define a priority list of pathways of environmental toxicological
concern, which are key to organism survival, growth and/or re-
production and describe the extent of their conservation across
species.
o Build a database designed around functional gene annotation to
enable full exploitation of data from all relevant species coupled
with improved mining tools to adequately interrogate this data.
o Address uncertainties in orthology assignment by re-designing
and deploying functional assays to report downstream/upstream
pathway-based effects.
o To develop cross-species relevant screening panels for the iden-
tification of priority pathways able to predict AOs of concern.
o To develop approaches linking the environmental/external con-
centration to the cellular/internal concentration at the target
tissue and the AO in order to understand the minimum level of
perturbation necessary to trigger toxicity.
o Improve the understanding of ADME processes across key relevant
biological classifications (e.g. family or species).
o Develop computational tools (i.e. models) to enable prediction or
classification of chemical clearance rates for species relevant to
RA, namely simplified PBK models.
● Decision-making challenges:
o Identify current technology and application gaps which need to be
addressed for the successful implementation of NAMs in RA.
o Establish and promote confidence in extrapolating effects across
species using mechanistic data, through the development of case-
studies
o Develop a new globally harmonized RA framework incorporating
NAMs and making use of all the data available (using well es-
tablished chemical read-across as well as cross species extra-
polation where possible)
o Improve the understanding of exposure scenarios, namely redu-
cing its granularity, so that those considerations can be better
incorporated into RA.
o Ensure early engagement and maximize communication of the
private sector (i.e. industry) and regulatory agencies to drive and
ensure future fit-for-purpose in the scientific/technical develop-
ment of NAMs.
As a last note from the workshop, it was remarked that it is im-
perative to continue the flow of these discussions to include the wider
scientific community, regulators, and industry, while continuing to
progress the development of novel scientific approaches to fully explore
the potential of NAMs. All relevant stakeholders should be involved in
this discussion to ensure its proper development. Only by having de-
velopers and end-users discussing the advancement of new approaches
together we can ensure that they are fit-for-purpose and meet the in-
novation and decision-makers' needs.
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